Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection

Autor(es):Mostrar menos -

Marangoni, Karina ^{[1, 2]} ; Neves, Adriana F. ^[3] ; Rocha, Rafael M. ^[4] ; Faria, Paulo R. ^[5] ; Alves, Patricia T. ^[1] ; Souza, Aline G. ^[1] ; Fujimura, Patricia T. ^[1] ; Santos, Fabiana A. A. ^[1] ; Araujo, Thaise G. ^[1] ; Ward, Laura S. ^[2] ; Goulart, Luiz R. ^{[1, 6]}

Afiliação do(s) autor(es)

^[1] Univ Fed Uberlandia, Lab Nanobiotechnol, Inst Genet & Biochem, Uberlandia, MG - Brazil

^[2] Univ Estadual Campinas, Lab Canc Mol Genet, Fac Med Sci, Campinas, SP - Brazil

^[3] Univ Fed Goias, Inst Biotechnol, Mol Biol Lab, Catalao, GO - Brazil

^[4] AC Camargo Canc Hosp, Sao Paulo, SP - Brazil

^[5] Univ Fed Uberlandia, Inst Biomed Sci, Histol Lab, Uberlandia, MG - Brazil

^[6] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 - USA

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 5, JUL 15 2015.
• Citações Web of Science: 11

Resumo

We described the selection of a novel nucleic acid antibody-like prostate cancer (PCa) that specifically binds to the single-stranded DNA molecule from a 277-nt fragment that may have been partially paired and bound to the PCA3 RNA conformational structure. PCA3-277 aptamer ligands were obtained, and the best binding molecule, named CG3, was synthesized for validation. Aiming to prove its diagnostic utility, we used an apta-qPCR assay with CG3-aptamer conjugated to magnetic beads to capture PCA3 transcripts, which were amplified 97-fold and 7-fold higher than conventional qPCR in blood and tissue, respectively. Histopathologic analysis of 161 prostate biopsies arranged in a TMA and marked with biotin-labeled CG3-aptamer showed moderate staining in both cytoplasm and nucleus of PCa samples; in contrast, benign prostatic hyperplasia (BPH) samples presented strong nuclear staining (78% of the cases). No staining was observed in stromal cells. In addition, using an apta-qPCR, we demonstrated that CG3-aptamer specifically recognizes the conformational PCA3-277 molecule and at least three other transcript variants, indicating that long non-coding RNA (lncRNA) is processed after transcription. We suggest that CG3-aptamer may be a useful PCa diagnostic tool. In addition, this molecule may be used in drug design and drug delivery for PCa therapy. (AU)

• Processo FAPESP: 12/24911-0 - Aplicação de aptâmeros de RNA no diagnóstico e terapêutica do câncer de próstata
• Beneficiário: Karina Marangoni
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado